DE69432268D1 - Verwendung von aminierten cyclodextrinen zum löslichmachen von als antiepileptika anzuwendenden dibenzazepinderivaten - Google Patents

Verwendung von aminierten cyclodextrinen zum löslichmachen von als antiepileptika anzuwendenden dibenzazepinderivaten

Info

Publication number
DE69432268D1
DE69432268D1 DE69432268T DE69432268T DE69432268D1 DE 69432268 D1 DE69432268 D1 DE 69432268D1 DE 69432268 T DE69432268 T DE 69432268T DE 69432268 T DE69432268 T DE 69432268T DE 69432268 D1 DE69432268 D1 DE 69432268D1
Authority
DE
Germany
Prior art keywords
antiepileptika
cyclodextrines
aminated
irrigation
dibenzazepine derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69432268T
Other languages
English (en)
Other versions
DE69432268T2 (de
Inventor
Florence Djedaini-Pilard
Bruno Perly
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Original Assignee
Commissariat a lEnergie Atomique CEA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Commissariat a lEnergie Atomique CEA filed Critical Commissariat a lEnergie Atomique CEA
Application granted granted Critical
Publication of DE69432268D1 publication Critical patent/DE69432268D1/de
Publication of DE69432268T2 publication Critical patent/DE69432268T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Nanotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69432268T 1993-12-22 1994-12-21 Verwendung von aminierten cyclodextrinen zum löslichmachen von als antiepileptika anzuwendenden dibenzazepinderivaten Expired - Fee Related DE69432268T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9315471A FR2713934B1 (fr) 1993-12-22 1993-12-22 Utilisation de cyclodextrines aminées pour la solubilisation aqueuse de composés hydrophobes, en particulier de molécules pharmaceutiquement actives.
PCT/FR1994/001503 WO1995017191A1 (fr) 1993-12-22 1994-12-21 Utilisation de cyclodextrines aminees pour la solubilisation aqueuse des dibenzazepines utilisables comme agent anti-epileptique

Publications (2)

Publication Number Publication Date
DE69432268D1 true DE69432268D1 (de) 2003-04-17
DE69432268T2 DE69432268T2 (de) 2003-12-04

Family

ID=9454243

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69432268T Expired - Fee Related DE69432268T2 (de) 1993-12-22 1994-12-21 Verwendung von aminierten cyclodextrinen zum löslichmachen von als antiepileptika anzuwendenden dibenzazepinderivaten

Country Status (7)

Country Link
EP (1) EP0735879B1 (de)
JP (1) JPH09506889A (de)
AU (1) AU680708B2 (de)
DE (1) DE69432268T2 (de)
FR (1) FR2713934B1 (de)
HU (1) HU219606B (de)
WO (1) WO1995017191A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10223783A1 (de) * 2002-05-29 2003-12-11 Boehringer Ingelheim Pharma Neue Formulierung zur parenteralen Applikation eines Na-Kanal-Blockers
US6828311B2 (en) 2002-05-29 2004-12-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Formulation for the parenteral application of a sodium channel blocker
US7851457B2 (en) 2004-01-29 2010-12-14 Innovative Biologics, Inc. β-Cyclodextrin derivatives
EP1846006A4 (de) 2005-01-28 2011-04-20 Pinnacle Pharmaceuticals Inc Beta-cyclodextrin-derivate als antibakterielle wirkstoffe
AU2013200204B9 (en) * 2005-09-30 2015-03-05 Lundbeck Llc Novel parenteral carbamazepine formulation
US20100204178A1 (en) 2006-10-02 2010-08-12 James Cloyd Novel parenteral carbamazepine formulation
AU2006299501B2 (en) * 2005-09-30 2012-11-29 Lundbeck Llc Novel parenteral carbamazepine formulation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY106598A (en) * 1988-08-31 1995-06-30 Australian Commercial Res & Development Ltd Compositions and methods for drug delivery and chromatography.
EP0491812A4 (en) * 1989-09-14 1992-11-04 Australian Commercial Research & Development Limited Drug delivery compositions
EP0435826A1 (de) * 1989-12-27 1991-07-03 Ciba-Geigy Ag Intravenöse Lösungen für Status Epilepticus
EP0518930A4 (en) * 1990-03-02 1993-09-15 Australian Commercial Research & Development Limited Cyclodextrin compositions and methods for pharmaceutical and industrial applications
US5231089A (en) * 1991-12-02 1993-07-27 University Of Florida Method of improving oral bioavailability of carbamazepine

Also Published As

Publication number Publication date
AU680708B2 (en) 1997-08-07
HU219606B (hu) 2001-05-28
AU1320095A (en) 1995-07-10
EP0735879A1 (de) 1996-10-09
HUT75333A (en) 1997-05-28
DE69432268T2 (de) 2003-12-04
HU9601737D0 (en) 1996-08-28
FR2713934B1 (fr) 1996-01-12
JPH09506889A (ja) 1997-07-08
WO1995017191A1 (fr) 1995-06-29
EP0735879B1 (de) 2003-03-12
FR2713934A1 (fr) 1995-06-23

Similar Documents

Publication Publication Date Title
DE69401817D1 (de) Verbesserungen zum herstellen von glasartigem silika
DE69512458D1 (de) Verwendung von Flavonoiden zum Schutz der Haare
DK0653179T3 (da) Adskillelig måtte
NO307150B1 (no) Tetning mellom to deler
DE69526055D1 (de) Zahnpflegemittel zum Mildern von Dentine-Empfindlichkeit
NO177246C (no) Fremgangsmåte for evaluering av parametre i forbindelse med de elastiske egenskapene til undergrunnsjordformasjoner
DE69130361D1 (de) Polymerisierbare porphyrine
NO954323D0 (no) Heterocykliske derivater
DE69604576D1 (de) Verwendung des Monoethanolamins zur Herstellung einer Zusammensetzung zur Ermittlung von empfindlicher Kopfhaut
DE69432268D1 (de) Verwendung von aminierten cyclodextrinen zum löslichmachen von als antiepileptika anzuwendenden dibenzazepinderivaten
DE59406163D1 (de) Messvorrichtung zum Vermessen der Form von Zylindern
DE59508900D1 (de) Verwendung von Dibrom-thiophen-carbonsäure-Derivaten als Mikrobizide
NO953634L (no) Fremgangsmåte for definerte delesjoner av DNA
FI942422A (fi) Menetelmä fysostigmiinin valmistuksessa käytettyjen välituotteiden enantioselektiivistä synteesiä varten
FI942888A0 (fi) Menetelmä pyranyylisyaaniguanidiinijohdanaisten valmistuksessa käyttökelpoisten välituotteiden valmistamiseksi
DE69125675D1 (de) In situ-Herstellung von Diisopinocampheylchloroboran
DE69110308D1 (de) Baueinheit zum Herstellen von vorgespannten Betongegenständen.
EE9400040A (et) Oftalmiliseks otstarbeks mõeldud kompositsioon
FI961178A0 (fi) Menetelmä syklisten cis-1-amino-2-alkanolien valmistamiseksi
FI962592A0 (fi) Uudet välituotteet keinotekoisina makeutusaineina käyttökelpoisten L-aspartyyli-D-alfa-aminoalkanoyyli-(S)-N-alfa-alkyylibentsyyliamidien syntetisoimiseksi
DE69323591D1 (de) Zusammensetzung zum Nachweis von Peroxid-aktivem Material
EE9400039A (et) Oftalmiliseks otstarbeks mõeldud kompositsioon
DE69418656D1 (de) 2-acyloxycephemderivate als elastaseinhibitoren
IT1268865B1 (it) Impianto di disidratazione fango
KR940026043U (ko) 절첩이 용이한 설합장

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee